Drug intelligence / Profile preview

CB104

Development stage: Preclinical
Lead developer: CellmAbs
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CB104 is a monoclonal antibody immunotherapy currently in the discovery and preclinical stages of development by CellmAbs. It is designed to target cancer-specific glycans, which are aberrant carbohydrate structures found on the surface of malignant cells. By specifically binding to these tumor-associated glycans, CB104 aims to leverage the immune system to identify and eliminate cancer cells. The program encompasses multiple variants (CB104 variant 1 and variant 2) and is being investigated for its potential application across various oncology indications.

Targets

CA19-9 (Carbohydrate antigen 19-9)

Beyond the preview

Go deeper on CB104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB104.

Explore the full profile